Walethmade%252525252525252525252520bromide

# Aclidinium Bromide *(Note: "Walethmade" is a misidentification of the long-acting muscarinic antagonist [LAMA] Aclidinium bromide.)* ## Overview Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) that acts as a potent competitive inhibitor of M3 receptors in airway smooth muscle. It provides bronchodilation via prolonged inhibition of acetylcholine-induced bronchoconstriction. It is administered via a dry powder inhaler (DPI). ## Primary Indications Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ## Adult Dosing * **Maintenance:** 400 mcg inhaled twice daily. * **Maximum:** 400 mcg twice daily. ## Pediatric Dosing * **Safety/Efficacy:** Not established. Not indicated for use in pediatric patients. ## Dose Adjustments * **Renal Impairment:** No dose adjustment required. * **Hepatic Impairment:** No dose adjustment required. * **Geriatric:** No dose adjustment required. ## Contraindications * Hypersensitivity to aclidinium bromide, atropine, or its derivatives. * Acute treatment of bronchospasm (not a rescue inhaler). ## Adverse Effects * **Common:** Headache, nasopharyngitis, cough, sinusitis. * **Serious:** Paradoxical bronchospasm (discontinue immediately), worsening of narrow-angle glaucoma, urinary retention (especially with prostatic hyperplasia/bladder neck obstruction), and anticholinergic effects (dry mouth). ## Key Drug Interactions * **Anticholinergics:** Concomitant use with other LAMAs or short-acting muscarinic antagonists (SAMAs) may increase the risk of systemic anticholinergic adverse effects. Avoid concurrent use. ## Monitoring * **Efficacy:** Periodic assessment of lung function (FEV1), reduction in rescue inhaler use, and symptomatic improvement. * **Safety:** Monitor for worsening of urinary retention or ocular symptoms (blurred vision, eye pain) suggestive of narrow-angle glaucoma. ## Clinical Pearls * **Administration:** It is critical to ensure the patient understands how to use the DPI; an audible "click" indicates the dose is ready after priming. * **Rescue Inhalers:** Patients must carry a rescue bronchodilator (e.g., albuterol) for acute symptoms. * **Paradoxical Bronchospasm:** Like all inhaled bronchodilators, if paradoxical bronchospasm occurs, discontinue therapy immediately and initiate alternative treatment. * **Storage:** Keep the inhaler in the sealed pouch until ready for use. *** **Educational Disclaimer:** This information is provided for educational purposes only. Clinical practice guidelines and drug labeling may change. Always verify current prescribing information, institutional protocols, and patient-specific factors via official drug monographs (e.g., Lexicomp, Clinical Pharmacology) or the package insert before prescribing or administering medication.